The SCE Dermatology presents a paradox that catches many candidates off guard. Dermatology is the most visual of all medical specialties — diagnosis depends on morphological pattern recognition, colour, texture, and distribution. Yet the SCE uses text-based best-of-five questions with no clinical photographs. Every rash, every lesion, every dermoscopic finding is described in words, and you must translate those descriptions into diagnoses and management plans.
This means the SCE Dermatology tests a specific skill that daily clinical practice does not directly develop: the ability to think dermatologically through language rather than images. A registrar who can diagnose lichen planus at a glance across the clinic room may struggle with a textual description of violaceous, polygonal, flat-topped papules with Wickham's striae on the flexor wrists — even though both require the same clinical knowledge.
Topic weighting
Inflammatory dermatoses — psoriasis and eczema — together account for roughly 16 per cent of the exam. This includes classification by severity (PASI for psoriasis, EASI for eczema), stepwise management from topical therapies through conventional systemics to biologics, and NICE technology appraisal eligibility criteria for biologic agents. The biologic landscape for psoriasis alone now includes adalimumab, secukinumab, ixekizumab, guselkumab, risankizumab, brodalumab, bimekizumab, and deucravacitinib — each with specific eligibility criteria, monitoring requirements, and positioning in the treatment algorithm.
Skin cancer accounts for approximately 14 per cent — melanoma (Breslow thickness, Clark level, staging, sentinel lymph node biopsy indications, adjuvant immunotherapy), BCC (subtypes, treatment options including Mohs), SCC (risk stratification, excision margins, immunosuppression-related SCC), and premalignant conditions (actinic keratosis, Bowen's disease). The exam tests management decisions rather than visual diagnosis — described features lead to a management question.
Cutaneous infection accounts for 8 per cent, covering bacterial (cellulitis, impetigo, necrotising fasciitis), viral (herpes simplex, varicella zoster, viral warts, molluscum), fungal (dermatophyte infections, candidiasis, pityriasis versicolor), and parasitic (scabies, pediculosis) infections. Blistering diseases account for 8 per cent — pemphigus vulgaris, bullous pemphigoid, dermatitis herpetiformis, linear IgA disease, epidermolysis bullosa acquisita. The histological features of each (acantholysis for pemphigus, subepidermal blistering with eosinophils for BP) are described textually and you must match them to the correct diagnosis.
Connective tissue disease skin manifestations, drug reactions (SJS/TEN, DRESS, AGEP, fixed drug eruption), hair disorders (alopecia areata, androgenetic alopecia, scarring alopecias), nail disorders, paediatric dermatology, dermatological surgery, and photobiology make up the remainder.
The biologic eligibility challenge
Biologic prescribing for psoriasis and eczema is one of the most heavily tested areas. You need to know the NICE TA eligibility criteria for each agent — typically PASI 10 or above and DLQI 10 or above despite adequate trial of standard systemic therapies (methotrexate, ciclosporin, acitretin for psoriasis; ciclosporin, methotrexate for eczema). You need to know which agents are first-line biologics, which are second-line, and the specific monitoring requirements for each. Dupilumab for eczema, secukinumab versus guselkumab for psoriasis, and the positioning of JAK inhibitors (baricitinib, upadacitinib, abrocitinib) are all testable at the level of clinical prescribing decisions.
Revision strategy
Three to four months. Spend the first month on inflammatory dermatoses and skin cancer — together they account for 30 per cent of the exam. Practise reading textual descriptions of skin lesions and translating them into differential diagnoses. Spend the second month on blistering diseases, drug reactions, infection, and connective tissue skin manifestations. Spend the third month on the remaining topics and mock exams.
Throughout your revision, practise the specific skill of interpreting described histopathology — acantholysis, spongiosis, interface dermatitis, granulomatous inflammation — since these appear regularly in exam questions.
iatroX's SCE Dermatology bank contains over 1,500 questions, all presenting clinical features as textual descriptions matching the real exam format. Biologic eligibility criteria, biopsy interpretation, and dermoscopy findings described in words are all covered. The adaptive algorithm ensures low-exposure domains like photobiology and genital dermatology receive proportional attention. All included at £29 per month or £99 per year.